MIDDLETON, Wis. and SARASOTA, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced that its Wisconsin Fertility Institute clinic has been included on Newsweek’s list of America’s Best Fertility Clinics for 2025. The America’s Best Fertility ...

Core Insights - NewGen plans to invest US$45 million in the UAE real estate market, focusing on properties near the Wynn Al Marjan Island integrated resort, marking a diversification from its traditional IVF business operations [1][2] - The investment is driven by Ras Al Khaimah's strong economic growth, political stability, and significant infrastructure developments, which are expected to enhance property values [2][5] - NewGen is also considering additional investments in Abu Dhabi's real estate market, which offers stability and long-term growth potential [2][3] Investment Strategy - The company has engaged UAE-based business development manager Samira Aissani to lead property acquisition initiatives, leveraging her extensive experience in UAE real estate [3] - NewGen is in advanced discussions for strategic plot acquisitions in Ras Al Khaimah and has established partnerships with prominent UAE developers [3][4] - A term sheet has been executed with Enclave Capital LLC to raise an additional US$45 million to support the UAE real estate expansion [4] Market Potential - The Wynn Al Marjan Island integrated resort, a multi-billion dollar development set to open in early 2027, is expected to drive demand for real estate in Ras Al Khaimah [2] - The region's strategic location, with 31% of the world's population within four hours' flying time, along with favorable investment policies, creates an ideal environment for real estate appreciation [2] - NewGen's CEO expressed confidence that the investment will deliver substantial returns and establish a strong foundation for future growth [5]

Core Insights - NewGen is expanding its digital asset portfolio by investing US$30 million in staking Solana, demonstrating a commitment to blockchain technology [1][2][3] - The investment will be financed through existing credit facilities totaling US$126 million [1] - This move follows an initial US$1 million investment in Bitcoin made in December 2024, indicating management's confidence in blockchain assets [3][4] Company Strategy - NewGen plans to establish a dedicated subsidiary focused on digital asset operations and investments, enhancing operational focus and strategic flexibility [3] - The investment in Solana is seen as a natural evolution of the company's digital asset strategy, reflecting a growing conviction in digital assets as a legitimate asset class [4] - The company aims to leverage Solana's high-speed transaction capabilities and staking rewards to create value for shareholders [2][4] Industry Context - Solana is recognized as a leading blockchain platform with a growing ecosystem of decentralized applications, which aligns with NewGen's strategic positioning [2] - The staking mechanism of Solana allows token holders to earn rewards while supporting network security and decentralization, presenting significant growth potential [2]

SARASOTA, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, will participate in a webcast fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29 ...

Core Insights - NewGenIvf Group Limited has launched First Fertility PGS Center Limited to target the Indian medical tourism market for fertility treatments [1][2] - The global fertility tourism market is projected to grow from US$709 million in 2023 to approximately US$13.08 billion by 2034, with a compound annual growth rate of 30.34% [2] - Thailand is becoming a preferred destination for fertility tourism due to its advanced medical infrastructure, cost-effective treatments, and supportive regulatory environment [2][4] Company Initiatives - First Fertility has developed culturally tailored services for Indian patients, including a dedicated hospitality lounge and Hindi-speaking staff [3] - The center offers comprehensive fertility treatments, including family balance through IVF, which is restricted in India but legally available in Thailand [3] - The initiative aims to create a culturally sensitive environment while providing access to advanced reproductive technologies [3] Market Positioning - Thailand's strategic advantages, such as visa-free entry for Indian nationals and a progressive regulatory environment, support the growth of the medical tourism sector [4] - First Fertility addresses the gap in culturally tailored fertility care for Indian patients, who represent a significant segment of the medical tourism market [4] - The CEO of NewGen emphasized the company's commitment to providing world-class fertility care while capitalizing on market opportunities in Southeast Asia [5]

Company now exclusively focused on the growing fertility market following the April 2025 announcement to divest a majority stake in Naya TherapeuticsSARASOTA, Fla., May 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced first quarter 2025 fi ...

Financial Data and Key Metrics Changes - First quarter revenue grew 16.5% to $324 million, primarily due to an increase in the number of clients and covered lives compared to the previous year [15] - Adjusted EBITDA increased by 15% to $58 million, with an adjusted EBITDA margin of 17.8%, slightly down from the previous year [22][28] - Net income was $15.1 million or $0.17 per diluted share, compared to $16.9 million or $0.17 per share in the prior year [22] Business Line Data and Key Metrics Changes - Fertility revenue increased 22% to $206 million, while pharmacy revenue grew 9% to $118 million [20] - ART cycles reached a record high of 16,160, reflecting a 9% growth year-over-year [19] Market Data and Key Metrics Changes - The CDC reported record low birth rates for women aged 25 and younger, while rates for women aged 30 to 44 continue to rise, indicating a shift in family planning trends [6][7] - Over 51% of all births in the U.S. now come from women aged 30 or older, highlighting the increasing need for fertility and maternity solutions [8] Company Strategy and Development Direction - The company is focusing on expanding its product portfolio and enhancing member experience, particularly in women's health and family building [5][9] - New services in maternity, postpartum, and menopause are expected to contribute up to 10% of revenue by 2028, although significant contributions are not anticipated in the near term [13][14] Management's Comments on Operating Environment and Future Outlook - Management raised full-year guidance, projecting revenue between $1.185 billion and $1.235 billion, reflecting growth of 1.5% to 5.8% [27] - The company expects continued member engagement at historical levels, despite potential variability in activity and treatments [25] Other Important Information - The company generated nearly $50 million in operating cash flow in the first quarter, nearly double the prior year period [23] - Total working capital as of March 31 was $331 million, with $256 million in cash and no debt [24] Q&A Session Summary Question: Historical seasonality of cycles per utilizer - Management indicated that guidance reflects uncertainty rather than a change in normal seasonality [30] Question: Drivers of gross margin expansion - Management noted that last year's revenue shortfall affected margins, and while they expect gross margin expansion for the full year, investments may impact margins [31][33] Question: 2026 selling season and RFP process - Management confirmed that they are not seeing a slowdown in RFP activities and are targeting to add at least 1 million new lives each year [38][43] Question: Incremental adjusted EBITDA margin - Management explained that the lower margin is due to investments in platform and product expansion, which are expected to impact the P&L this year [44] Question: Interest in new modules - The menopause product is seeing higher engagement due to a larger addressable audience compared to maternity products [47] Question: Impact of tariffs on costs - Management stated that existing tariffs have not significantly impacted costs, and potential tariffs on pharmaceuticals are not expected to affect their operations [53] Question: Pricing benefits in ART cycles - Management clarified that growth is driven by engagement and activity rather than pricing [68]

Core Insights - NewGen has rebranded its MicroSort technology to NewGenSort, integrating it into its product offerings to enhance reproductive solutions in Asia [1][4] - NewGenSort technology allows for the separation of X and Y chromosome-bearing sperm cells, facilitating family planning and prevention of genetic diseases [2][3] Company Overview - NewGenIvf Group Limited is a comprehensive fertility services provider in Asia, offering a range of fertility treatments to couples and individuals [5] - The company operates clinics in Thailand, Cambodia, and Kyrgyzstan, providing services such as infertility treatments, egg and sperm donation, and surrogacy [5] Technology Applications - NewGen plans to utilize its sperm-sorting technology through two applications: MicroSort for gender selection and MacroSort for addressing male reproductive challenges [3] - MicroSort enables couples to balance family composition, while MacroSort focuses on avoiding sex-linked genetic disorders [3] Strategic Vision - The integration of NewGenSort is seen as a pivotal advancement for the company, expected to accelerate growth and expand market share across Asia [4] - The technology aims to provide personalized reproductive solutions, enhancing the overall family health and prosperity for clients [4]

SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served mo ...

SARASOTA, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics, today announced fourth quarter and full year 2024 financial results. Q4 2024 Financial Highlights (all metrics compared to Q4 2023 unless otherwise noted) Revenue was $1,685,966, an increase of 22% compared to $1,381,754.Con ...